Replimune
18 Commerce Way
Woburn
Massachusetts
01801
United States
Website: http://replimune.com/
Email: info@replimune.com
About Replimune
Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune intends to progress these rapidly through clinical trials and to combine these with checkpoint blockade at an early stage of clinical development.
YEAR FOUNDED:
April 2015
LEADERSHIP:
Executive Chairman & Director: Philip Astley-Sparke
CEO & Director: Robert Coffin, Ph.D.
COO: Colin Love, Ph.D.
CBO: Pamela Esposito, Ph.D.
CMO: Howard Kaufman, M.D.
VP, Clinical Development: Susan Doleman
Sr. VP of Regulatory Affairs and QA: Anne Marie Woodland
VP, Research: Suzanne Thomas, Ph.D.
SCIENCE:
Please click here for Replimune's science.
85 articles about Replimune
-
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
5/9/2023
Replimune Group, Inc. announced that members from the Replimune management team will host investor meetings at the Piper Sandler Spring Biopharma Symposium being held from Wednesday, May 17 through Thursday, May 18, 2023 at the Encore Boston Harbor in Boston, MA.
-
Replimune to Present at Two Upcoming Investor Conferences - March 8, 2023
3/8/2023
Replimune Group, Inc. today announced that members from the Replimune management team will present and host investor meetings at the following two conferences.
-
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
2/7/2023
Replimune Group, Inc. today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.
-
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
1/4/2023
Replimune Group, Inc. announced the appointment of Christopher Sarchi as Replimune’s Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune’s Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately.
-
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023
1/4/2023
Replimune Group, Inc. announced the grant of inducement equity awards to Chris Sarchi, the Company’s newly appointed Chief Commercial Officer.
-
Replimune Announces Pricing of Public Offering - December 09, 2022
12/9/2022
Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50 per share.
-
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
12/7/2022
Replimune Group, Inc. today announced that the Company has entered into a Master Clinical Trial Collaboration and Supply Agreement in relation to Replimune’s RP2/3 program in colorectal cancer (CRC) and hepatocellular carcinoma (HCC).
-
Replimune Announces Proposed Public Offering - December 07, 2022
12/7/2022
Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.
-
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
12/7/2022
Replimune Group, Inc. today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.
-
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
11/23/2022
Replimune Group, Inc. today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET.
-
Replimune Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
11/3/2022
Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2022 and provided a business update.
-
Replimune to Present at Two Upcoming November 2022 Investor Conferences
11/2/2022
Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced that members from the Replimune management team will present and host investor meetings at the following two conferences.
-
Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
10/7/2022
Replimune Group, Inc. today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc.
-
Replimune Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update
8/4/2022
Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced financial results for the fiscal first quarter ended June 30, 2022 and provided a business update.
-
Replimune to Present at Two Upcoming Investor Conferences - Aug 01, 2022
8/1/2022
Replimune Group, Inc. announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
-
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
6/3/2022
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from the company’s Board of Directors.
-
Replimune to Present at the Jefferies Healthcare Conference
6/2/2022
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 AM ET.
-
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2022
Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced multiple presentations at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.
-
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
3/30/2022
Replimune Group, Inc. today announced updated data from completed cohorts of the Phase 2 part of the IGNYTE clinical trial in non-melanoma skin cancer (NMSC) and melanoma.
-
Replimune to Host Virtual Investor Event on March 30, 2022
3/21/2022
Replimune Group Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced that members of its executive team and Key Opinion Leaders will host an investor event to present updated data from the completed cohorts of the Phase 2 IGNYTE clinical trial in non-melanoma skin cancer and melanoma.